

RAS Inhibitor A122


RAS(MULTI)

oral tri-complex RAS(MULTI)(ON) inhibitor
undisclosed relative RMC-6236 in Ph. I/II
for solid tumors

from structure-based design of previous KRAS
tricomplex inhibitors

Press Release, October 2023

REVOLUTION MEDICINES, REDWOOD CITY, CA



ACBI3


pan-KRAS

subcutaneous pan-KRAS degrader
preclinical proof-of-concept

structure-based design from KRASi
w/ VHL ligase binder

bioRxiv, October 2023

BOEHRINGER INGELHEIM, AT / CETPD, UK



ABBV-467

MCL-1


IV selective MCL-1 inhibitor

Ph. I for relapsed/refractory multiple
myeloma terminated

from NMR-based fragment screen and
structure-based design

Commun. Med., October 2023

ABBVIE, NORTH CHICAGO, IL



ABBV-CLS-484

PTPN2/N1


oral first-in-class PTPN2/N1 active site inhibitor

Ph. I for locally advanced or metastatic tumors

structure-based design from
thiadiazolidinone dioxide

Nature, October 2023

ABBVIE, NORTH CHICAGO, IL



FHD-286

BRG1/BRM


oral selective allosteric BRG1/BRM ATPase inhibitor

Ph. I for metastatic uveal melanoma

from screen for BRG1/BRM inhibitors

Press Release, October 2023

FOGHORN THERAPEUTICS, CAMBRIDGE, MA



MRT-2359

GSPT1


oral GSPT1-directed molecular glue degrader

Ph. I/II for selected cancers

from HTS of glue degrader library and AI-driven opt.

Press Release, October 2023

MONTE ROSA THERAPEUTICS, MA / BASEL, CH



BMS-502

DGKα/ζ


DGKα/ζ inhibitor

preclinical for PD-1 resistant tumors

from HTS and optimization

Sci. Transl. Med., October 2023

BRISTOL MYERS SQUIBB, CAMBRIDGE, MA



NT-0796

NLRP3


oral brain-penetrant NLRP3 inhibitor prodrug

Ph. Ib/IIa for cardiovascular risk and
neuroinflammation

from SAR and prodrug development of known
NLRP3 inhibitor CP-456,773

J. Med. Chem., October 2023

NODTHERA, ESSEX, UK



PF-07202954

DGAT2


oral extended-half-life DGAT2 inhibitor

Ph. I discontinued due to ervogastat success

from half-life extension of ervogastat

ACS Med. Chem. Lett., October 2023

PFIZER, CAMBRIDGE, MA / GROTON, CT



MTK458

PINK1

oral brain penetrant PINK1 activator

preclinical for Parkinson's Disease

from screen of kinetin analogs

Press Release, October 2023

MITOKININ, CA / ABBVIE, IL